Cellu Tissue Holdings, Inc. Announces Second Quarter Fiscal 2010 Results
</pre> <p>ALPHARETTA, Ga., <chron>Oct. 7</chron> /CNW/ -- Cellu Tissue Holdings, Inc. (the "Company" or "Cellu Tissue"), a leading North American producer of consumer-oriented private label tissue with a growing presence in the value retail tissue market, today reported net income of <money>$2.7 million</money> for the quarter ended <chron>August 27, 2009</chron> compared to a loss of <money>$0.2 million</money> in the second quarter 2008.</p> <p/> <p>"The Company has continued to execute its strategy of leveraging our vertically integrated hardroll tissue manufacturing to grow our tissue converting operations," said Russell C. Taylor, President and Chief Executive Officer of Cellu Tissue Holdings. "As a result of continued improvement in the business, we believe we will exceed the high end of our previously communicated Adjusted EBITDA guidance of <money>$75 million to $80 million</money> for the current fiscal year."</p> <p/> <p>As previously announced, in the second quarter of fiscal year 2009, the Company completed its acquisition of the Long Island, New York and Thomaston, <location>Georgia</location> tissue converting operations of Atlantic Paper & Foil ("APF"). Accordingly, the results for the three and six months ended <chron>August 27, 2009</chron> are impacted by the effects of APF's operating results, as highlighted below.</p> <pre> Second Quarter 2010 Financial and Operating Results </pre> <p>Net sales for the Fiscal 2010 three month period increased <money>$4.8 million</money>, or 3.6%, to <money>$137.8 million</money> from <money>$133.0 million</money> for the comparable prior year period. During the Fiscal 2010 three month period, we sold 89,328 tons of tissue hardrolls, machine-glazed tissue hardrolls and converted tissue products, an increase of 4,291 tons, or an increase of 5.0% over the comparable prior year period. During the quarter, we in-sourced an additional 6,046 tons of hardrolls for our converting operations that were previously purchased on the hardroll market in the prior year. This served to reduce external hardroll shipments by a similar amount and improved our overall sales mix due to higher selling prices for converted tissue products. This is consistent with our strategy to increase the vertical integration of the acquired operations, supporting improved quality control and profitability. Net selling price per ton decreased to <money>$1,519</money> during the current period from <money>$1,554</money> during the prior year period. This decrease in price primarily reflects the downward pricing pressure brought on by lower pulp prices, which was partially offset by the impact of mix improvements.</p> <p/> <p>Gross profit was <money>$22.6 million</money> for the Fiscal 2010 three month period, or an increase of <money>$11.6 million</money> from <money>$11.0 million</money> in the comparable prior year period. As a percentage of net sales, gross profit increased to 16.4% in the Fiscal 2010 three month period from 8.3% in the fiscal 2009 three month period. The improvement was primarily driven by the overall volume, mix and selling price changes as discussed above, as well as favorable improvements in pulp pricing and lower energy costs.</p> <p/> <p>Income from operations for the second quarter ended <chron>August 27, 2009</chron> was <money>$16.2 million</money> compared to <money>$5.7 million</money> for the comparable period in the prior fiscal year. The overall increase is the result of the increase in gross profit as noted above, offset partially by higher selling, general and administrative expense in connection with increased incentive compensation expense.</p> <pre> Debt Refinancing </pre> <p>During the second quarter of Fiscal 2010 the Company refinanced its long-term debt, which resulted in higher overall interest rates and extended the overall maturity of the majority of long-term debt. The new 11-1/2% Senior Secured Notes due in 2014 ("2014 Notes") generated cash proceeds of <money>$245.7 million</money>. These proceeds were primarily used to retire all of the 9-3/4% Senior Secured Notes due in 2010 ("2010 Notes"). Interest expense for the current quarter was <money>$12.3 million</money>, compared to <money>$6.1 million</money> in the prior year period. The current quarter includes the effects of extinguishing our 2010 Notes and the issuance of our 2014 Notes. Non-recurring costs of the refinancing include both the write-off of deferred financing fees of <money>$2.2 million</money> and incremental interest expense of <money>$1.7 million</money> due to the period of time that elapsed between the issuance of the 2014 Notes and the extinguishment of the 2010 Notes. The remaining increase is primarily attributable to the higher interest rates and debt issuance costs related to the 2014 Notes.</p> <pre> Segment Operating Results Tissue </pre> <p>Net sales for our tissue segment were <money>$107.8 million</money> during the Fiscal 2010 three month period, an increase of <money>$4.4 million</money>, or 4.2% from <money>$103.4 million</money> in the comparable prior year period. The increase was due primarily to increased sale volumes, an improved mix with respect to converting tons sold, and moderate price improvement. Net selling price per ton increased to <money>$1,625</money> for the Fiscal 2010 three month period from <money>$1,605</money> for the Fiscal 2009 three month period. This increase in net selling price per ton was primarily the result of improvements in product mix as a result of higher converted tissue sales, and to a smaller extent, an increase in converted product selling prices, partially offset by downward pricing pressure brought on by lower pulp prices. The increase in converting tons sold reflects continued organic growth in our converting business and results from the APF Acquisition for the full three month period in Fiscal 2010, compared to only two months of ownership in the Fiscal 2009 three month period. For the Fiscal 2010 three month period, we sold 66,312 tons of tissue compared to 64,416 tons in the Fiscal 2009 three month period.</p> <p/> <p>Operating income was <money>$15.4 million</money> compared to <money>$6.1 million</money>, driven by the factors discussed above, and was also due to reduced fiber and energy prices and increased sales of our converted tissue products, which leveraged our ability to incrementally use more internally manufactured hardrolls.</p> <pre> Machine-Glazed Tissue </pre> <p>Net sales for our machine-glazed tissue segment for the Fiscal 2010 three month period were <money>$27.9 million</money>, a decrease of <money>$0.8 million</money> or 2.8%, compared to <money>$28.7 million</money> in the comparable prior year period. Tons sold during the fiscal 2010 period increased 11.6%, but this increase was offset by a decline in selling prices associated with lower pulp prices. Net selling price per ton was <money>$1,213</money> for the Fiscal 2010 three month period compared to <money>$1,393</money> per ton for the Fiscal 2009 three month period. For the Fiscal 2010 three month period, we sold 23,016 tons of machine-glazed tissue compared to 20,621 tons in the Fiscal 2009 three month period.</p> <p/> <p>Operating income was <money>$1.3 million</money> in the current quarter compared to <money>$0.3 million</money> in the Fiscal 2009 period. The improvement was primarily attributable to lower pulp and energy prices, along with favorable machine productivity.</p> <pre> Foam </pre> <p>Net sales and operating income for our foam segment was <money>$2.1 million</money> and <money>$0.6 million</money> in the fiscal 2010 period, respectively, compared to <money>$0.9 million</money> and <money>$0.2 million</money> in the prior year period. The increase was primarily due to the timing of the APF Acquisition and lower resin prices, the primary raw material used to manufacture our foam products.</p> <pre> Adjusted EBITDA </pre> <p>Earnings before interest, taxes, depreciation, amortization and special items (Adjusted EBITDA) for the second quarter ended <chron>August 27, 2009</chron> totaled <money>$23.3 million</money>, compared to <money>$13.2 million</money> for the comparable period in the prior fiscal year.</p> <pre> Notice Relating to the Use of Non-GAAP Measures </pre> <p>Attached to this press release are tables setting forth the Company's fiscal second quarter consolidated statements of operations, financial position and selected consolidated financial data, including information concerning the Company's cash flow position, selected consolidated segment data, reconciliations of consolidated net income to consolidated EBITDA and reconciliations of consolidated EBITDA to consolidated Adjusted EBITDA. EBITDA and Adjusted EBITDA are not measures of performance under U.S. generally accepted accounting principles and should not be considered in isolation or used as a substitute for income from operations, net income, net cash provided by operating activities or other operating or cash flow data prepared in accordance with generally accepted accounting principles. The Company believes EBITDA and Adjusted EBITDA are useful to investors because they are used by management to evaluate the Company's financial performance. Adjusted EBITDA is defined as EBITDA adjusted for items which are expenses that are considered outside the normal operations of the business.</p> <p/> <p>Cellu Tissue's management invites you to listen to its conference call on <chron>October 8, 2009</chron> at <chron>10:00 a.m. EST</chron> regarding fiscal second quarter 2010 consolidated financial results. The dial-in number is (800) 230-1074 or International (612) 288-0337; participant code 118371. A taped replay of the conference call will be available after <chron>12:30 p.m.</chron> <chron>October 8, 2009</chron> until <chron>October 22, 2009</chron>. The number to call for the taped replay is (800) 475-6701 or International (320) 365-3844, access code 118371.</p> <p/> <p>Cellu Tissue Holdings, Inc. is a leading North American producer of consumer-oriented private label tissue products with a growing presence in the value retail tissue market.</p> <p/> <p>For more information, contact Cellu Tissue Holdings, Inc. at <a href="http://www.cellutissue.com">www.cellutissue.com</a>.</p> <p/> <p>The statements contained in this release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the Company's future financial performance. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements included in this document are based upon information available to Cellu Tissue as of the date hereof, and Cellu Tissue assumes no obligation to update any such forward-looking statements. Such statements and any other forward-looking statements are subject to risks, assumptions and uncertainties that may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements, including risks related to energy and fiber costs, the growth of our converted tissue business and synergies relating to the APF Acquisition and any other risks described in our Annual Report on Form 10-K for the fiscal year ended <chron>February 28, 2009</chron> and subsequent filings with the SEC.</p> <p/> <p> </p> <p> </p> <pre> CELLU TISSUE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) </pre> <p> </p> <pre> For the three For the six months ended months ended ------------------------- -------------------------- August 27, August 28, August 27, August 28, 2009 2008 2009 2008 ---------- ----------- ------------ ------------ Net sales $137,796,650 $133,012,856 $256,724,872 $247,540,417 Cost of goods sold 115,154,471 122,012,927 214,269,375 224,752,584 ----------- ----------- ------------ ------------ Gross profit 22,642,179 10,999,929 42,455,497 22,787,833 </pre> <p> </p> <pre> Selling, general and administrative expenses 5,164,488 4,163,350 10,434,429 9,123,192 Terminated acquisition- related transaction costs - 65,044 - 140,044 Stock compensation expense 191,260 226,987 422,480 445,493 Amortization expense 1,079,268 802,435 2,135,692 802,435 ---------- ---------- ----------- ------------ Income from operations 16,207,163 5,742,113 29,462,896 12,276,669 </pre> <p> </p> <pre> Interest expense, net 12,331,443 6,061,057 18,837,994 11,040,745 Foreign currency loss 356,287 127,700 713,226 84,620 Other expense (income) (355,871) 8,910 (372,445) 38,418 ---------- ----------- ------------ ------------ Income before income tax (benefit) expense 3,875,304 (455,554) 10,284,121 1,112,886 </pre> <p> </p> <pre> Income tax (benefit) expense 1,157,830 (208,471) 5,255,782 367,499 ---------- ----------- ------------ ------------ Net income (loss) $2,717,474 $(247,083) $5,028,339 $745,387 ========== =========== ============ ============ </pre> <p> </p> <p> </p> <p> </p> <pre> CELLU TISSUE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) </pre> <p> </p> <pre> August 27, February 28, 2009 2009 ------------ ------------ ASSETS Current Assets: Cash and cash equivalents $22,026,586 $361,035 Receivables, net 50,608,827 54,065,899 Inventories 39,240,582 47,216,049 Prepaid expenses and other current assets 2,762,231 2,085,774 Income tax receivable 114,076 174,084 Deferred income taxes 6,076,578 3,515,295 ------------ ------------ Total Current Assets 120,828,880 107,418,136 </pre> <p> </p> <pre> Property, Plant and Equipment, net 304,560,737 301,987,941 Goodwill 41,020,138 41,020,138 Other intangibles 29,536,785 31,672,477 Other assets 10,501,950 1,948,108 ------------ ------------ Total Assets $506,448,490 $484,046,800 ============ ============ </pre> <p> </p> <p> </p> <pre> LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Bank overdrafts $- $3,285,420 Revolving line of credit - 18,530,824 Accounts payable 22,200,416 16,726,143 Accrued expenses 26,334,867 26,548,639 Accrued interest 7,042,583 10,160,124 Other current liabilities 16,730,056 17,448,707 Current portion of long-term debt 760,000 760,000 ------------ ------------ Total Current Liabilities 73,067,922 93,459,857 </pre> <p> </p> <pre> Long-term debt, less current portion 268,352,692 242,361,944 Deferred income taxes 80,065,490 75,110,277 Other liabilities 6,091,431 5,378,059 </pre> <p> </p> <pre> Stockholders' Equity: Common stock, Class A, $.01 par value, 1,000 shares authorized, 100 shares issued and outstanding 1 1 Capital in excess of par value 71,371,341 70,948,860 Accumulated earnings 8,726,410 3,698,071 Accumulated other comprehensive loss (1,226,797) (6,910,269) ------------ ------------ Total Stockholders' Equity 78,870,955 67,736,663 ------------ ------------ Total Liabilities and Stockholders' Equity $506,448,490 $484,046,800 ============ ============ </pre> <p> </p> <p> </p> <p> </p> <pre> CELLU TISSUE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS </pre> <p> </p> <p> (Unaudited)</p> <p> </p> <pre> Six Months Ended August 27, August 28, 2009 2008 ------------ ------------ </pre> <p> </p> <pre> Cash flows from operating activities Net income $5,028,339 $745,387 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 12,050,067 11,722,167 Amortization of intangibles 2,135,692 802,435 Amortization of deferred financing fees 479,707 70,197 Accretion of debt discount 976,448 600,929 Loss from write-off of discount on notes 1,911,471 - Write-off of deferred financing fees 299,803 - Stock-based compensation 422,480 445,493 Deferred income taxes 2,393,930 183,283 Loss on disposal of fixed asset 147,241 - Loss from natural gas swaps - 835,484 Changes in operating assets and liabilities, net of effects of acquisitions: Receivables 4,287,654 (10,094,518) Inventories 8,699,026 (611,272) Prepaid expenses, other current assets and income tax receivable (757,153) 254,655 Other 368,092 (665,725) Accounts payable, accrued expenses and accrued interest 2,429,452 2,436,384 ------------ ------------ Total adjustments 35,843,910 5,979,512 ------------ ------------ Net cash provided by operating activities 40,872,249 6,724,899 </pre> <p> </p> <pre> Cash flows from investing activities Cash paid for acquisition, net of cash acquired - (63,829,401) Capital expenditures (11,162,014) (4,820,549) ------------ ------------ Net cash used in investing activities (11,162,014) (68,649,950) </pre> <p> </p> <pre> Cash flows from financing activities Equity investment by shareholders - 15,001,466 Bank overdrafts (3,285,420) - Borrowings on revolving line of credit, net 22,350,147 51,000,000 Payments on revolving line of credit, net (40,880,971) (37,800,000) Payments on long-term debt (380,000) (380,000) Retirement of long-term debt (222,255,572) - Payment of deferred financing fees (9,346,462) (847,813) Net proceeds from bond offering 245,738,400 36,900,000 ------------ ------------ Net cash (used in) provided by financing activities (8,059,878) 63,873,653 </pre> <p> </p> <pre> Effect of foreign currency 15,194 (228,359) ------------ ------------ Net increase in cash and cash equivalents 21,665,551 1,720,243 Cash and cash equivalents at beginning of period 361,035 883,388 ------------ ------------ Cash and cash equivalents at end of period $22,026,586 $2,603,631 ============ ============ </pre> <p> </p> <p> </p> <p> </p> <pre> CELLU TISSUE HOLDINGS, INC. CONSOLIDATED BUSINESS SEGMENT INFORMATION (Unaudited) </pre> <p> </p> <p> </p> <p> </p> <pre> BUSINESS SEGMENTS Three Months Ended August 27, August 28, 2009 2008 ------------ ------------ NET SALES: Tissue $107,781,026 $103,413,826 Machine-Glazed Tissue 27,925,877 28,718,124 Foam 2,089,747 880,906 ------------ ------------ Consolidated $137,796,650 $133,012,856 ============ ============ INCOME FROM OPERATIONS: Tissue $15,356,475 $6,112,624 Machine-Glazed Tissue 1,326,574 253,267 Foam 603,382 178,657 ------------ ------------ Segment income from operations 17,286,431 6,544,548 Amortization expense (1,079,268) (802,435) ------------ ------------ Consolidated $16,207,163 $5,742,113 ============ ============ </pre> <p> </p> <p> </p> <p> </p> <pre> Six Months Ended August 27, August 28, 2009 2008 ------------ ------------ </pre> <p> </p> <pre> NET SALES: Tissue $201,248,387 $189,210,876 Machine-Glazed Tissue 51,519,942 57,448,635 Foam 3,956,543 880,906 ------------ ------------ Consolidated $256,724,872 $247,540,417 ============ ============ </pre> <p> </p> <pre> INCOME FROM OPERATIONS: Tissue $27,711,329 $12,167,787 Machine-Glazed Tissue 2,666,960 732,660 Foam 1,220,299 178,657 ------------ ------------ Segment income from operations 31,598,588 13,079,104 Amortization expense (2,135,692) (802,435) ------------ ------------ Consolidated $29,462,896 $12,276,669 ============ ============ </pre> <p> </p> <p> </p> <p> </p> <pre> CELLU TISSUE HOLDINGS, INC, RECONCILIATION OF CONSOLIDATED NET INCOME TO EBITDA (Unaudited) ($ in thousands) </pre> <p> </p> <p> </p> <pre> Three Months Ended August 27, August 28, 2009 2008 ------------ ------------ NET INCOME (LOSS) $2,717 $(247) Add back: Depreciation 6,122 5,868 Amortization 1,079 802 Interest expense 12,331 6,061 Income tax expense (benefit) 1,159 (208) ------------ ------------ EBITDA $23,408 $12,276 ============ ============ </pre> <p> </p> <pre> Six Months Ended August 27, August 28, 2009 2008 ------------ ------------ NET INCOME $5,028 $745 Add back: Depreciation 12,050 11,722 Amortization 2,136 802 Interest expense, net 18,838 11,041 Income tax expense 5,256 367 ------------ ------------ EBITDA $43,308 $24,677 ============ ============ </pre> <p> </p> <p> </p> <p> </p> <pre> CELLU TISSUE HOLDINGS, INC. RECONCILIATION OF CONSOLIDATED EBITDA TO CONSOLIDATED ADJUSTED EBITDA (Unaudited) ($ in thousands) </pre> <p> </p> <pre> Three Months Three Months Ended Ended August 27, 2009 August 28, 2008 --------------- --------------- EBITDA $23,408 $12,276 Add back (a) : Equipment/facility moves (2) 20 - Insurance recovery (3) (346) - Stock compensation (4) 191 227 Inventory step-up adjustment (5) - 283 APF Transition Costs (6) 334 Terminated Acquisition Costs (7) 115 --------------- --------------- ADJUSTED EBITDA $23,273 $13,235 =============== =============== </pre> <p> </p> <pre> Six Months Six Months Ended Ended August 27, 2009 August 28, 2008 --------------- --------------- </pre> <p> </p> <pre> EBITDA $43,308 $24,677 Add back (a) : Mill Fire (1) 250 - Equipment/facility moves (2) 373 - Insurance recovery (3) (346) - Stock compensation (4) 422 445 Inventory step-up adjustment (5) - 284 APF Transition Costs (6) - 334 Terminated Acquisition Costs (7) - 233 Mississippi Sales & Use Tax (8) 258 --------------- --------------- ADJUSTED EBITDA $44,007 $26,231 =============== =============== </pre> <p> </p> <pre> (a) Add backs represent adjustments to EBITDA for items which are either noncash in nature or expenses that are considered outside the normal operations of the business as more fully explained below: (1) Costs incurred with respect to fire damage at one of our mills. (2) Costs incurred to move Hauppauge operations to Central Islip which was completed during the three months ended August 27, 2009. (3) Insurance recovery as a result of equipment that was damaged in transit. (4) Non cash compensation expense related to the vesting of restricted stock awards and stock option awards. (5) Inventory step up adjustment related to purchase accounting for APF acquisition. (6) Transition costs related to the APF acquisition. (7) Deal costs for acquisitions that were ultimately not completed. (8) Sales and use tax assessment based on audit of prior periods.
For further information: Cellu Tissue Holdings, Inc. +1-678-393-2651 Web Site: http://www.cellutissue.com
Share this article